Compare EU & MRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EU | MRVI |
|---|---|---|
| Founded | 2009 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Metals and Minerals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 464.5M | 472.8M |
| IPO Year | 2011 | 2020 |
| Metric | EU | MRVI |
|---|---|---|
| Price | $2.09 | $3.48 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 7 |
| Target Price | $4.00 | ★ $4.57 |
| AVG Volume (30 Days) | ★ 3.0M | 1.1M |
| Earning Date | 06-09-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 14.29 |
| EPS | ★ N/A | N/A |
| Revenue | $58,334,000.00 | ★ $185,743,000.00 |
| Revenue This Year | $17.41 | $11.80 |
| Revenue Next Year | $95.45 | $7.74 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 163.38 | N/A |
| 52 Week Low | $1.01 | $1.67 |
| 52 Week High | $4.19 | $4.11 |
| Indicator | EU | MRVI |
|---|---|---|
| Relative Strength Index (RSI) | 35.66 | 52.07 |
| Support Level | N/A | $3.25 |
| Resistance Level | $2.56 | $3.65 |
| Average True Range (ATR) | 0.18 | 0.19 |
| MACD | -0.06 | 0.04 |
| Stochastic Oscillator | 27.94 | 58.74 |
enCore Energy Corp together with its subsidiary, is engaged in the acquisition and exploration of resource properties of uranium resource properties in the United States. The holds a portfolio of uranium assets located in New Mexico, South Dakota, Wyoming, Texas, Utah, Colorado, and Arizona in the USA, and is advancing its properties with a focus on utilizing in-situ recovery. The company's Projects are South Texas Operations, Dewey-Burdock Project, Gas Hills Project, Crownpoint & Hosta Butte Project, PFN (Prompt Fission Neutron) Technology, and Other Assets.
Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.